Faculty of MedicineLibrary of the School of Health Sciences
Μιχαήλ Κουτσιλιέρης, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Παναγούλα Αγγελογιάννη, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπουσα
Μαρία Κυριακοπούλου-Λυμπέρη, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Ελένη Κοτσιφάκη, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Κλειώ Μαυραγάνη, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Αναστάσιος Φιλίππου, Αναπληρωτής Καθηγητής, Ιατρικής Σχολή, ΕΚΠΑ
Αντώνιος Χατζηγεωργίου, Επίκουρος Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Έκφραση της kisspeptin και του υποδοχέα της GPR54 στον καρκίνο του προστάτη
Expression of kisspeptin and its receptor GPR54 in prostate cancer
Prostate cancer is the second most commonly diagnosed cancer in men and the sixth cause of mortality among all cancers. Disease recurrence and tumor progress, often occurring after the initial radical therapy, cause increased mortality. It is well known that the current diagnostic evaluation and screening for prostate cancer is mainly based on PSA testing. In addition to prostate cancer, PSA increase may occur in various noncancerous conditions, such as benign hyperplasia and inflammation of the prostate gland. PSA is an organ specific but not cancer specific marker, thus providing the opportunity for further tumor marker investigation.
Furthermore the rapid developments in molecular biology and genetics have revealed the heterogeneity and complexity of prostate cancer disease and they have opened new paths in understanding the molecular mechanisms of prostate cancer with promising results. Over the past few decades the role of kisspeptin (KISS1) and its receptor GPR54 (KISS1R) have gained increasing interest among researchers globally. In the present study the expression of KISS1-KISS1R has been examined, in prostate cancer tissue specimen after radical prostatectomy. The expression of KISS1, KISS1R has been immunohistochemically detected and evaluated in relation with tumor Grade, tumor stage, Gleason score, presence of PIN and surgical margins. Results of the present study have shown a higher expression of KISS1 and KISS1R in early stage localized tumors (Stage ≤IIb) compared to patients with advanced (Stage ≥III) tumor. A decreased expression of KISS1 and KISS1R was associated with an increase in tumor stage, Gleason score and Gleason Grade Group. Patients with advanced tumor stage, higher Gleason score and higher Gleason Grade Group showed a low expression rate of both KISS1 and KISS1R. In conclusion a downregulation of both KISS1 and KISS1R was detected in advanced prostate cancer. The role of KISS1 might be promising in the future diagnostic evaluation and risk assessment of prostate cancer. Further studies are necessary in order to examine the wide spectrum of function of kisspeptin in tumor biology and its potential clinical use in prostate cancer.
Main subject category:
KISS1, KISS1R, GPR54, Kisspeptin, Prostate cancer
Number of references: